BG
ALT icon

Bellevue Group’s Altimmune ALT Stock Holding History

Bellevue Group’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,056,793
Closed -$5.28M – 143
2025
Q1 		$5.28M Buy
1,056,793
+111,347
+12% +$705K 0.12% 85
2024
Q4 		$6.82M Buy
945,446
+81,786
+9% +$625K 0.13% 88
2024
Q3 		$5.3M Buy
863,660
+263,660
+44% +$1.79M 0.09% 97
2024
Q2 		$3.99M Buy
+600,000
New +$4.43M 0.06% 99

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bellevue Group's ALT Position: Q2 2025 in Review

Bellevue Group sold out of Altimmune (ALT) in Q2 2025, closing a stake of 1,056,793 shares — an estimated $5.28M sold.

Bellevue Group first reported a position in ALT in Q2 2024 and held it in 4 quarters. The position peaked at $6.82M in Q4 2024. 180 funds tracked by Wall St. Rank hold ALT as of Q2 2025.

  • Bellevue Group reported no remaining Altimmune position as of Q2 2025 after selling out during the quarter.
  • Bellevue Group sold 1,056,793 Altimmune shares in Q2 2025, an estimated $5.28M.
  • Bellevue Group first reported a position in Altimmune in Q2 2024 and held it in 4 quarters.
  • Bellevue Group's Altimmune position peaked at $6.82M in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Altimmune as of Q2 2025.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.